Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
about
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosisA comparative analysis of human and mouse islet G-protein coupled receptor expression.Autophagy and its link to type II diabetes mellitusLixisenatide: first global approval.Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryExendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats.Longstanding insulin dependent diabetics may not require insulin after the introduction of GLP-1 analogues.Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins.Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in miceDrug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatmentExendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.Liraglutide: a review of its use in the management of type 2 diabetes mellitus.Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.Exenatide extended-release: a review of its use in type 2 diabetes mellitus.Extra-pancreatic effects of incretin-based therapies.Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.An overview of new GLP-1 receptor agonists for type 2 diabetes.DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposityCentral GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in miceExendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.Effects of exendin-4 on male reproductive parameters of d-galactose induced aging mouse model.Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential.Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development.Recent progress in unraveling the complexities of receptor biology: towards new therapeutics.Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
P2860
Q28481242-8BC1B0E8-8EDD-4172-8B4C-89DA271FA82EQ33577144-FD0BD888-6477-4184-A3E3-A027D9421674Q33821526-539E2C5F-33A8-46CA-8CE6-615A4541EAA2Q34337281-4B95915C-2345-4175-B3C8-A19EC97E9DA9Q34362412-E359E0C1-1CC4-470D-A4D3-78D8A8F3756BQ35061438-3122E8B1-E18D-42AF-8CCE-87F6F9009058Q35175857-94494C58-6790-4D3A-8E2F-D71F0BF638E4Q35996636-26E7F44A-510F-4F5E-9B5F-16EAA34B2019Q36041923-10F449CB-9BDC-4603-8458-48D9BC734983Q37179909-4B499357-0AD3-489A-842E-8951C6610D3AQ37509313-2B65EB4E-28CA-4B1B-941F-AF2CD9D221E0Q37577129-89917622-82CF-4298-A78B-6281ABC57BA0Q37671303-717007DF-1B8F-4A2D-824B-1980CC7C3483Q37956408-5E19E3CE-646A-43C6-A70F-DFA92337A648Q38026582-74EE75E8-34CE-4DB4-AF21-CB5151F11A05Q38032321-634CB69D-FE54-4398-B9D5-040C3F50E2E5Q38194069-886B3B9C-760A-4117-9196-A577CF9C4DBDQ38234927-10774B41-E00B-48C6-9E4B-14DDE07A1185Q38261573-0B0F5912-E5F3-41FE-9921-706DA0DEF3FCQ38639922-DC2159EB-12F3-44EE-A47B-764E0B20BF13Q41153628-4E4615E4-3FF6-46BC-A1F7-3D70A3391B6BQ41553213-CA4F6337-70A0-4CBC-8CB5-57BFABB85CE0Q42388707-429DDA58-9BE4-4450-B307-26615800C8B0Q43110903-985790F0-D953-4734-9C77-77680DCF35B0Q44080580-12D3118D-5376-4488-A1D1-2A45BC58851EQ45378064-102B24BD-CA70-4549-95D6-22E9112E81DCQ47335504-F4D42E80-52B9-464F-AD2F-CEE3BF3F8DA7Q48293433-985EA0ED-B08A-4455-920A-C2748364E2EEQ51331106-A2563E9E-8BE2-4041-8F70-5C03963D48BBQ51754121-16FFAF13-7900-42EF-A198-2FCC9D4D093E
P2860
Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Glucagon-like peptide-1 analog ...... : current and emerging agents.
@en
Glucagon-like peptide-1 analog ...... : current and emerging agents.
@nl
type
label
Glucagon-like peptide-1 analog ...... : current and emerging agents.
@en
Glucagon-like peptide-1 analog ...... : current and emerging agents.
@nl
prefLabel
Glucagon-like peptide-1 analog ...... : current and emerging agents.
@en
Glucagon-like peptide-1 analog ...... : current and emerging agents.
@nl
P2860
P1433
P1476
Glucagon-like peptide-1 analog ...... : current and emerging agents.
@en
P2093
Baptist Gallwitz
P2860
P304
P356
10.2165/11592810-000000000-00000
P577
2011-09-01T00:00:00Z
P5875
P6179
1013236626